Overview

A Study of LY3471851 in Participants With Eczema

Status:
Active, not recruiting
Trial end date:
2022-08-16
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Nektar Therapeutics